Scancell Holdings (SCLP)

 

Latest News

Immuno-Oncology Summit Europe 2017

RNS Number: 8784Z Scancell Holdings Plc 20 March 2017 20 March 2017 Scancell Holdings Plc ("Scancell" or the "Company") Scancell to present at the Immuno-Oncology Summit Europe 2017 Professor Lindy Durrant, Scancell's CSO, to chair and present in a session entitled: "Combining Checkpoint Inhibitors with Other Modalities" Scancell Holdings plc, ('Scancell' o...

Scancell eyes fundraising for Phase II SCIB1 trial

Scancell Holdings said that in 2017 it will concentrate on raising the necessary funds to enable the commencement of a Pha...

Hardman Research: SCIB development update

RNS Number: 2051Z Scancell Holdings Plc 13 March 2017 Hardman Research: SCIB development update SCIB development update: Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for u...

Holding(s) in Company

RNS Number: 1310Y Scancell Holdings Plc 01 March 2017 TR-1: notification of major interests in shares 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Scancell Holdings Plc 2. Reason for the notification (please tick the appropriate box or boxes) An acquisition or disposal of voting rights An acquisition or disposal of...

All News

DateHeadlineSource
20-03-17Immuno-Oncology Summit Europe 2017RNS
13-03-17Scancell eyes fundraising for Phase II SCIB1 trialStockMarketWire
13-03-17Hardman Research: SCIB development updateRNS
01-03-17Holding(s) in CompanyRNS
31-01-17Scancell widens H1 pretax lossStockMarketWire
31-01-17Interim ResultsRNS
30-01-17Scancell in partnership to advance lung cancer clinical trialsStockMarketWire
30-01-17Partnership to Advance Lung Cancer Clinical TrialsRNS
03-01-17Research Update - AmendmentRNS
03-01-17Scancell Holdings issues research updateStockMarketWire
03-01-17Research UpdateRNS
14-11-16World Immunotherapy Congress and Biotech and MoneyRNS
18-10-16Results of AGMRNS
10-10-16Preparing SCIB2 for clinical study in lung cancerRNS
26-09-16Hardman Report: New frontiers in T-cell activationRNS
23-09-16Notice of AGM - AmendmentRNS
23-09-16Scancell Holdings schedules AGMStockMarketWire
23-09-16Notice of AGMRNS
16-09-16Scancell widens H1 pretax loss StockMarketWire
16-09-16Final ResultsRNS
07-09-16NewsMakers in the Biotech Industry ConferenceRNS
22-08-16Appointment of Non-Executive DirectorRNS
21-07-16Eurogentec manufacturing agreementRNS
20-07-16Scancell extends Ichor commercial optionStockMarketWire
20-07-16Extension to Ichor Commercial OptionRNS
13-07-16Peer-reviewed publication on Moditope? platformRNS
06-07-16Scancell notes SCIB1 compelling survival data StockMarketWire
06-07-16SCIB1 compelling survival data in melanomaRNS
29-06-16Second Price Monitoring ExtnRNS
29-06-16Price Monitoring ExtensionRNS
17-06-16FTSE flies amid Brexit pause as gold, oil off highsStockMarketWire
17-06-16Scancell suspends dosing of SCIB1 immediatelyStockMarketWire
17-06-16SCIB1 Drug Product SupplyRNS
02-06-16Scancell updates on ImmunoBody vaccine StockMarketWire
02-06-16Development of ImmunoBody? VaccineRNS
18-05-16Broker Forecast - Panmure Gordon issues a broker note on Scancell Holdings PLCStockMarketWire
18-05-16Opens US Headquarters in San DiegoRNS
19-04-16Director/PDMR ShareholdingRNS
11-04-16Holding(s) in CompanyRNS
06-04-16Holding(s) in CompanyRNS

RSS feeds

  • Editorial news feed for LSE:SCLP Editorial
  • Regulatory news feed for LSE:SCLP Regulatory